Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Late-onset Compared to Adult-onset Multiple Sclerosis: Differences in Clinical and Cognitive Profiles and Impact of Sex
Multiple Sclerosis
P1 - Poster Session 1 (8:00 AM-9:00 AM)
6-004
The proportion of patients with MS onset occurring after 45 years of age (i.e., LOMS) is increasing. Although previous studies suggested different clinical features between LOMS and AOMS, a comprehensive evaluation including also cognitive profiles and sex influence has not been fully undertaken yet.
To compare clinical and cognitive characteristics between late-onset (LO) multiple sclerosis (MS) and adult-onset (AO) MS and investigate sex-related differences.
Sixty-one LOMS patients (females=31) and 122 disease duration- and sex-matched AOMS patients (females=62) underwent comprehensive neurological and neuropsychological evaluations. Differences in clinical (type of onset, Expanded Disability Status Scale [EDSS], 9-hole Peg Test, and Timed 25-Foot Walk test [T25FWT]) and neuropsychological features (performance and frequency of impairment of global cognitive functions and of specific domains, presence and severity of fatigue and depression) were explored, considering also sex.
Compared to AOMS, LOMS patients exhibited higher prevalence of motor onset, of reaching EDSS 3.0 milestone, and worse T25FWT (p≤0.036). LOMS patients were also more frequently cognitively impaired, with significantly worse performance in visual memory and higher prevalence of attention and verbal fluency impairment (p≤0.034). LOMS males had a more frequent motor onset, significantly worse T25FWT, higher prevalence of more cognitive impairment, and higher prevalence of depression compared to AOMS males (p≤0.026). LOMS females performed significantly worse in visual memory, but had significantly lower fatigue compared to AOMS females (p≤0.025). Compared to AOMS females, males showed worse T25FWT and worse performance and higher prevalence of impairment in verbal memory and attention (p≤0.042). Compared to LOMS females, males showed worse performance and higher prevalence of impairment in attention, and higher frequency of depression (p≤0.035). 
LOMS patients exhibited worse clinical and cognitive features compared to AOMS patients, regardless from sex. Male patients showed more severe clinical and cognitive impairment in both AOMS and LOMS.
Authors/Disclosures
Damiano Mistri, MSC (Università Vita-Salute San Raffaele)
PRESENTER
Mr. Mistri has nothing to disclose.
Nicolò Tedone (San Raffaele hospital) No disclosure on file
Paolo Preziosa (Ospedale San Raffaele) Mr. Preziosa has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Bristol Myers Squibb . Mr. Preziosa has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Sanofi Genzyme. Mr. Preziosa has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Novartis. Mr. Preziosa has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Roche. Mr. Preziosa has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Merck.
Matteo Azzimonti No disclosure on file
Massimo Filippi, MD, FAAN (Ospedale San Raffaele, Neuroimaging Research Unit) Dr. Filippi has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Alexion, Almirall, Biogen, Merck, Novartis, Roche, Sanofi;. Dr. Filippi has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion, Biogen, Bristol-Myers Squibb, Merck, Novartis, Roche, Sanofi, Sanofi-Aventis, Sanofi- Genzyme, Takeda. Dr. Filippi has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Bayer, Biogen, Celgene, Chiesi Italia SpA, Eli Lilly, Genzyme, Janssen, Merck-Serono, Neopharmed Gentili, Novartis, Novo Nordisk, Roche, Sanofi, Takeda, and TEVA. Dr. Filippi has received personal compensation in the range of $5,000-$9,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Springer Nature. The institution of Dr. Filippi has received research support from Biogen Idec, Merck-Serono, Novartis, Roche, the Italian Ministry of Health, the Italian Ministry of University and Research, and Fondazione Italiana Sclerosi Multipla.
Maria A. Rocca (Neuroimaging Research Unit) Maria Assunta Rocca has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biogen, Bristol Myers Squibb, Eli Lilly, Janssen, Roche. Maria Assunta Rocca has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for AstraZaneca, Biogen, Bristol Myers Squibb, Bromatech, Celgene, Genzyme, Horizon Therapeutics Italy, Merck Serono SpA, Novartis, Roche, Sanofi and Teva. The institution of Maria Assunta Rocca has received research support from MS Society of Canada, the Italian Ministry of Health, the Italian Ministry of University and Research, and Fondazione Italiana Sclerosi Multipla.